Weight change associated with valproate and lamotrigine monotherapy in  patients with epilepsy

Biton, Victor; Mirza, Waqar; Montouris, Georgia; Vuong, Alain; Hammer, Anne E.; Barrett, Pamela S.

doi:10.1212/wnl.56.2.172

Cited by 217 publications

(153 citation statements)

References 34 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Alterations in energy intake or expenditure can result from, or be associated with, changes in biological mechanisms, including hormone levels (Martin et al, 2009). Similar findings were observed in other studies also (Biton, et al, 2001;El-Khatib, et al, 2007;Kanemura et al, 2012). Monotherapy with Phenytoin caused hypocalcaemia in 4 and anemia in 3 patients respectively.…”

Section: Resultssupporting

confidence: 90%

A Study on the Adverse Drug Reactions Induced by Anti Epileptic Drugs in the Epileptic Patients

Jayalekshmi¹,

Palanisamy²,

Sambathkumar³

et al. 2016

J App Pharm Sci

View full text Add to dashboard Cite

Epilepsy is a chronic disorder of the brain that affects people worldwide. The aim of this work was to study the adverse drug reactions (ADRs) induced by the antiepileptic drugs (AEDs) in epileptic patients. This prospective study was carried out for six months, from April 2014 to September 2014, in a tertiary teaching care hospital, Erode. The study included epileptic patients, both male and female of all age groups, undergoing treatment with AEDs. A total of 180 epileptic patients were monitored, 60% were male and 40% were females. Majority of the study population were adults. Majority of the epileptic patients were affected with generalized seizure (46.66%). Monotherapy was preferred more (71.1%) over combination therapy (34.44%). Sodium valproate (24.4%) was the most prescribed drug in monotherapy followed closely by Phenytoin (18.3%). Most prescribed two drug combination was of Sodium valproate and Carbamazepine (8.3%) followed by Phenytoin and Phenobarbitone (6.67%). Most common ADR was memory loss, hepatotoxicity, aggression and reduced learning. Sodium valproate was found to induce more number of ADRs followed by Carbamazepine and Phenytoin. Treatment with antiepileptic drugs was continued in all cases, except in three cases of skin rashes.

show abstract

Section: Resultssupporting

confidence: 90%

A Study on the Adverse Drug Reactions Induced by Anti Epileptic Drugs in the Epileptic Patients

Jayalekshmi¹,

Palanisamy²,

Sambathkumar³

et al. 2016

J App Pharm Sci

View full text Add to dashboard Cite

show abstract

Section: Dose-related Side Effectsmentioning

confidence: 99%

“…Weight gain is a frequent problem, and increase in body weight and body mass index following VPA treatment have recently been studied (10,23). These studies show that weight gain occurs within the first ten weeks of treatment and is in the order of six kilograms (10,23). Weight gain during VPA therapy is associated with metabolic changes like a decrease in â-oxidation of fatty acids (18), increased insulin and insulin/glucose ratios (31), and increased leptin and insulin levels (120).…”

Section: Dose-related Side Effectsmentioning

confidence: 99%

Valproate: Past, Present, and Future

2003

View full text Add to dashboard Cite

Preclinical studies have been carried out during the past four decades to investigate the different mechanisms of action of valproate (VPA). The mechanisms of VPA which seem to be of clinical importance include increased GABAergic activity, reduction in excitatory neurotransmission, and modification of monoamines. These mechanisms are discussed in relation to the various clinical uses of the drug. VPA is widely used as an antiepileptic drug with a broad spectrum of activity. In patients, VPA possesses efficacy in the treatment of various epileptic seizures such as absence, myoclonic, and generalized tonicclonic seizures. It is also effective in the treatment of partial seizures with or without secondary generalization and acutely in status epilepticus.The pharmacokinetic aspects of VPA and the frequent drug interactions between VPA and other drugs are discussed. The available methods for the determination of VPA in body fluids are briefly evaluated.At present, investigations and clinical trials are carried out and evaluated to explore the new indications for VPA in other conditions such as in psychiatric disorders, migraine and neuropathic pain. Furthermore, the toxicity of VPA, both regarding commonly occurring side effects and potential idiosyncratic reactions are described. Derivatives of VPA with improved efficacy and tolerability are in development.

show abstract

“…Of these, the clinically most important is the valproate-associated increase in body weight. This appears to be cumulative over the course of many years of treatment (Biton et al, 2001), and seems to be an important risk factor for the development of non-alcoholic fatty liver disease, which occurs in 61 % of patients (Luef et al, 2004). Valproate is a fatty acid derivative and competes with free fatty acids for albumin binding, and, as a GABAergic agonist, is known to be involved in insulin secretion from pancreatic beta-cells.…”

Section: Effects On Body Weightmentioning

confidence: 99%

Adverse Metabolic Effects of Antiepileptic Drug Treatment

Nakken¹

2011

Novel Treatment of Epilepsy

View full text Add to dashboard Cite

Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy

Cited by 217 publications

References 34 publications

A Study on the Adverse Drug Reactions Induced by Anti Epileptic Drugs in the Epileptic Patients

A Study on the Adverse Drug Reactions Induced by Anti Epileptic Drugs in the Epileptic Patients

Valproate: Past, Present, and Future

Adverse Metabolic Effects of Antiepileptic Drug Treatment

Contact Info

Product

Resources

About